

Adda Nathalie  
 Form 4/A  
 September 21, 2018

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Adda Nathalie

2. Issuer Name and Ticker or Trading Symbol  
 ENANTA PHARMACEUTICALS INC [ENTA]

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)  
 \_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)  
 Sr. VP & Chief Medical Officer

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
 07/18/2018

C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)  
 07/19/2018

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 \_\_\_ Form filed by More than One Reporting Person

WATERTOWN, MA 02472

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	V	Amount	Price			
Common Stock	07/18/2018		S <sup>(1)</sup>			1,185 <sup>(6)</sup>	\$ 123.7155 <sup>(2)</sup>	5,370 <sup>(6)</sup>	D	
Common Stock	07/18/2018		S <sup>(1)</sup>			445	\$ 124.2008 <sup>(3)</sup>	4,925 <sup>(6)</sup>	D	
Common Stock	07/18/2018		S <sup>(1)</sup>			1,621	\$ 125.6029 <sup>(4)</sup>	3,304 <sup>(6)</sup>	D	

Edgar Filing: Adda Nathalie - Form 4/A

Common Stock      07/18/2018      S<sup>(1)</sup>      904      D      \$ 126.3953      2,400 <sup>(6)</sup>      D <sup>(5)</sup>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**      SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Transaction (Instr. 5)
--	--	--------------------------------------	--	--------------------------------	---	--	---	--	---

## Reporting Owners

**Reporting Owner Name / Address**

Adda Nathalie  
C/O ENANTA PHARMACEUTICALS, INC.  
500 ARSENAL STREET  
WATERTOWN, MA 02472

**Relationships**

Director    10% Owner    Officer    Other

Sr. VP & Chief Medical Officer

## Signatures

/s/ Nathaniel S. Gardiner as attorney-in-fact      09/21/2018

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.
- (2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$122.925 to \$123.87, inclusive.

## Edgar Filing: Adda Nathalie - Form 4/A

- (3) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$123.95 to \$124.48, inclusive.
- (4) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$125.09 to \$126.07, inclusive.
- (5) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$126.12 to \$126.90, inclusive.

- The Form 4 filed by the reporting person on July 19, 2018 is being amended to correct: (i) a scrivener's error with regard to the number of shares reported as disposed in column 4 and (ii) the corresponding amount of securities beneficially owned following reported transactions in column 5. The subsequent Form 4 filed by the reporting person on August 21, 2018 does not reflect the correction made in this amendment to the amount of securities beneficially owned following reported transactions.
- (6)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.